Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.

•Bempedoic acid added to high-dose atorvastatin significantly lowers low-density lipoprotein cholesterol.•Atherogenic lipids and high-sensitivity C-reactive protein are lowered by bempedoic acid added to atorvastatin.•Bempedoic acid does not meaningfully increase steady-state atorvastatin exposure.•The combination of bempedoic acid and high-dose atorvastatin is well tolerated.